Stockscreener 앱 받기
2.13
3.62%
-0.10
전일 마감가:
$2.23
열려 있는:
$2.25
하루 거래량:
183.80K
Relative Volume:
1.64
시가총액:
$20.58M
수익:
-
순이익/손실:
$-45.57M
주가수익비율:
-0.3381
EPS:
-6.3
순현금흐름:
$-38.56M
1주 성능:
-41.44%
1개월 성능:
-48.21%
6개월 성능:
-20.40%
1년 성능:
-63.39%
1일 변동 폭
$2.00
$2.26
1주일 범위
$2.00
$4.60
52주 변동 폭
$2.00
$6.30
Sab Biotherapeutics Inc Stock (SABS) Company Profile
명칭
Sab Biotherapeutics Inc
전화
305-845-2813
주소
777 W 41ST ST, MIAMI BEACH
SABS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.1304 | 20.58M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.26 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.29 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.27 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.25 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
121.42 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 개시 | Oppenheimer | Outperform |
| 2021-11-05 | 개시 | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc 주식(SABS)의 최신 뉴스
Why Is SAB BIO Stock Trading Lower On Tuesday? - Benzinga
SAB BIO Announces Positive Topline Phase 1 Clinical Results - GlobeNewswire
Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn
Revolutionary Type 1 Diabetes Drug Aces Safety Tests, Outpatient Treatment Now Possible - StockTitan
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 - Marketscreener.com
SAB Biotherapeutics (SABS) Stock Price, News & Analysis - MarketBeat
SAB BIO Announces R&D Webinar Event to Review Phase 1 - GlobeNewswire
SAB BIO to Present Phase 1 Type 1 Diabetes Treatment Data in Upcoming R&D Webinar - StockTitan
10 Best Diabetes Stocks To Buy Under $10 - Insider Monkey
Here’s Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Down 60.5% in December - Defense World
SAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To Consider - Simply Wall St
SABS FY2024 EPS Reduced by Brookline Capital Management - Defense World
SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023) - Yahoo Finance
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire
SAB Bio's Q3 Loss Widens to $10.3M Despite Progress in Diabetes Drug Trial - StockTitan
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference - GlobeNewswire
Critical Comparison: Sana Biotechnology (NASDAQ:SANA) & SAB Biotherapeutics (NASDAQ:SABS) - Defense World
SAB Biotherapeutics Inc (SABS) Getting Ready To Launch, Waiting For The Long Term Buyers - Stocks Register
Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Declines By 12.7% - Defense World
Saba Capital Income & Opportunities Fund II (NYSE:SABA) Major Shareholder Sells $37,672.38 in Stock - Defense World
Metric Analysis: Cassava Sciences Inc (SAVA)’s Key Ratios in the Limelight - The Dwinnex
Healthy Upside Potential: Sabre Corp (SABR) - SETE News
Assembly Biosciences keeps Neutral rating after Phase 1a study results - Investing.com
DSMB endorses continuation of Alzheimer's drug trials - Investing.com India
Cassava Sciences Unusual Options Activity For September 23 - Benzinga
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely - Yahoo Finance
Renaissance Technologies LLC Lowers Stock Position in SBA Communications Co. (NASDAQ:SBAC) - Defense World
Sabre Corporation (SABR): Among the Worst AI Stocks To Buy Under $10 - Yahoo Finance
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - Morningstar
SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Oppenheimer - Defense World
SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update - Defense World
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - GlobeNewswire
SAB Biotherapeutics (NASDAQ:SABS) Given “Buy” Rating at Chardan Capital - Defense World
SAB BIO Provides SAB-142 Clinical Trial Progress Update at - GlobeNewswire
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the - The Bakersfield Californian
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting - StockTitan
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - GlobeNewswire
SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated by Analysts at Oppenheimer - Defense World
How To Buy SAB Biotherapeutics, Inc. Stock Online in August 2024 - Traders Union
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG - Barchart
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, - openPR
Chardan Capital Analysts Boost Earnings Estimates for SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Receives Buy Rating from HC Wainwright - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Chardan Capital - Defense World
SABS stock touches 52-week low at $2.3 amid market challenges - Investing.com
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - GlobeNewswire
Seasonal Influenza Treatment Market Size 2032 | SAb - openPR
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - GlobeNewswire
SAB BIO Appoints Lucy To as Chief Financial Officer - citybiz
Sab Biotherapeutics Inc (SABS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.69%
4.93%
자본화:
|
볼륨(24시간):